Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Granero R, Fernandez-Aranda F, Aymami N, Gomez-Pena M, Fagundo AB, Sauchelli S, Del Pino-Gutierrez A, Moragas L, Savvidou LG, Islam MA, Tarrega S, Menchon JM, Jimenez-Murcia S. Subtypes of pathological gambling with concurrent illegal behaviors. J Gambl Stud. 2015 Dec;31(4):1161-78. doi: 10.1007/s10899-014-9499-5.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.